AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, ...

AVAC and Access Bridge today issued a global call to action urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three ...

Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded ...

US Government’s Opportunity to Reach At Least Three Million with LEN by 2027 AVAC’s new publication, Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and ...

The term autonomous means that a person can make his or her own decisions about what to do and what to agree to. Researchers must respect that individuals should make their own informed decisions ...

Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US ...

AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention ...

New York, NY, June 18, 2025 — AVAC welcomes the U.S. Food and Drug Administration (FDA) approval of injectable lenacapavir (LEN) for the prevention of HIV as pre-exposure prophylaxis (PrEP). LEN, ...

Injectable lenacapavir for PrEP (LEN) is rolling out across Africa faster than any HIV prevention option to date. This Friday, South Africa will become the ninth African country to introduce LEN.

Our team compiled a list of AVAC’s top 10 takeaways from AIDS 2026. These topics sparked discussions and ideas among our team and AVAC’s larger partner network, and will carry our work well into the ...

A first-in-class once-weekly oral combination of islatravir plus lenacapavir achieved viral suppression as effectively as daily oral antiretroviral therapy (ART) at week 48 in the ISLEND trial, ...